ASSURE TECH (HANGZHOU) CO., LTD. Assure Tech (Hangzhou) Co., Ltd. Stock
Equities
688075
CNE100004ZC0
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.32 CNY | +0.48% |
|
-4.20% | -12.31% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 6.17B 854M | Sales 2023 | 503M 69.69M | Capitalization | 5.12B 709M |
|---|---|---|---|---|---|
| Net income 2022 | 3.04B 422M | Net income 2023 | 142M 19.66M | EV / Sales 2022 | 0.67 x |
| Net cash position 2022 | 3.5B 484M | Net cash position 2023 | 2.07B 287M | EV / Sales 2023 | 6.06 x |
| P/E ratio 2022 |
2.51
x | P/E ratio 2023 |
36.3
x | Employees | 950 |
| Yield 2022 |
5.93% | Yield 2023 |
-
| Free-Float | 22.38% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.48% | ||
| 1 week | -4.20% | ||
| Current month | -2.11% | ||
| 1 month | +7.62% | ||
| 3 months | +3.12% | ||
| 6 months | -18.52% | ||
| Current year | -12.31% |
1 week
34.96
37.00
1 month
32.4537.85
Current year
28.7640.58
1 year
28.7650.91
3 years
28.76150.82
5 years
28.76150.82
10 years
28.76150.82
| Managers | Title | Age | Since |
|---|---|---|---|
Shi Sheng Ling
CEO | Chief Executive Officer | 52 | 09-04-30 |
Jiong Zhang
CHM | Chairman | 39 | 10-02-28 |
Min Kang
DFI | Director of Finance/CFO | 49 | 22-12-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Juan Ying Zhou
BRD | Director/Board Member | 59 | 19-08-25 |
Shi Sheng Ling
CEO | Chief Executive Officer | 52 | 09-04-30 |
Xue Ying Jiang
BRD | Director/Board Member | 50 | 14-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 35.32 | +0.48% | 293,804 |
| 24-05-16 | 35.15 | -1.07% | 407,393 |
| 24-05-15 | 35.53 | -2.34% | 328,841 |
| 24-05-14 | 36.38 | +0.22% | 360,628 |
| 24-05-13 | 36.3 | -1.55% | 491,362 |
End-of-day quote Shanghai S.E., May 16, 2024
More quotes
Assure Tech Hangzhou Co Ltd is a China-based company mainly engaged in the research and development of point-of-care testing (POCT) reagents and instruments. The Company's products include antigen and antibody raw materials, immunochromatographic reagents and testing equipment, and dry biochemical reagents and testing equipment. The Company's POCT products cover eight areas of drug testing, infectious disease testing, chronic disease testing, pregnancy testing, tumor testing, myocardial testing, biochemical testing, and allergen testing. The Company's products are sold to the United States, Germany, Britain, Canada and other countries.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.31% | 622M | |
| -4.67% | 12.32B | |
| -5.19% | 8.07B | |
| +9.45% | 5.91B | |
| +28.50% | 5.52B | |
| -8.09% | 4.21B | |
| -55.31% | 2.99B | |
| +13.49% | 2.73B | |
| -1.34% | 2.43B | |
| +32.24% | 2.29B |
- Stock Market
- Equities
- 688075 Stock
